John Libbey Eurotext

Gériatrie et Psychologie Neuropsychiatrie du Vieillissement

MENU

Chemotherapy-related cognitive impairment or « chemobrain »: concept and state of art Volume 15, issue 1, Mars 2017

Tables

Authors
1 Service de neurologie, Service de santé des armées, HIA de Percy, Clamart, France
2 Service de neurologie 2, Hôpital de la Pitié-Salpêtrière, Paris, France
3 UMR MD4 8257 CNRS, Université Paris Descartes, SSA, Paris, France
4 Pôle immunologie-infectiologie-inflammation-endocrinologie I3E/USR, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
5 UMR 1086 Inserm, Centre régional de lutte contre le cancer François Baclesse, Caen, France
6 Institut Gustave Roussy, Villejuif, France
7 Ecole du Val-de-Grâce, Service de santé des armées, Paris, France
* Tirés à part

Cognitive complaints are frequent in patients who received chemotherapy for a non-CNS cancer. These observations have been described as « chemobrain ». However, studies results are contradictory concerning the implication of chemotherapy in the onset of cognitive defects. Moreover, other factors as mood, anxiety and fatigue are often associated in this population and could be confounding. This article present principal results of research in human experiencing chemobrain, concerning clinical presentation, neuropsychological examination, imaging techniques and treatment possibilities. Physiopathological hypothesis are presented. The implication of hormonotherapy is also discussed.